FGF19 and cancer: As a note of caution, increased levels of fibroblast growth factor-19 (FGF19) following OCA treatment were observed in the AESOP trial, as anticipated by others, thus prudence regarding a potentially increased malignancy risk may be indicated particularly in PSC with its inherent high risk of cancer.